ArticleiScience2026
Early detection and subtyping of gastric cancer: A cell-free DNA fragmentome-based liquid biopsy method.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-free DNA (cfDNA) in plasma provides attractive opportunities for early cancer diagnosis. This study aimed to establish gastric cancer (GC) artificial intelligence algorithms (GC-AIAs) based on cfDNA fragmentome for GC's early detection and subtyping. Whole-genome sequencing data were obtained from the training cohort of 404 participants, the internal testing cohort of 173 participants, and the independent validation cohort of 299 participants. Seven classes of cfDNA fragmentomic features were analyzed and employed to build the GC-AIA employing a stack ensemble model. The model's AUC in the internal testing cohort was 0.958 (95% confidence interval [CI]: 0.931-0.985) and that in the independent validation cohort was 0.951 (95% CI: 0.926-0.975). The GC-AIA showed high performance for various staged/differentiated GC detection and molecular subtyping. The stage shift analysis showed a notable increase in diagnosed stage Ⅰ patients. Our methodology built on the cfDNA fragmentomics exhibited encouraging preliminary performance in early detection and subtyping of GC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.